Search research articles
Contact Us
Filters
Showing results (11-20 of 104) with videos related to
Page
of 11
Sort By:
Pathology Oncology Research : POR
|
December 27, 2006
Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues
Katalin Derecskei, Judit Moldvay, Krisztina Bogos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 15, 2016
Differences in the Epidemiology of Rare EGFR Mutations in Different Populations
Zoltan Lohinai, Gyula Ostoros, Judit Moldvay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 23, 2015
Reply to Rare Versus Artifactual EGFR Mutations
Zoltan Lohinai, Gyula Ostoros, Judit Moldvay, et al.
Magyar Onkologia
|
December 18, 2010
[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer]
György Losonczy, Csaba Máthé, Veronika Müller, et al.
Biomarker Research
|
February 23, 2016
A robust prognostic gene expression signature for early stage lung adenocarcinoma
Marcin Krzystanek, Judit Moldvay, David Szüts, et al.
Magyar Onkologia
|
April 11, 2013
[Analysis of drug therapy of lung cancer in Hungary]
Judit Moldvay, György Rokszin, Zsolt Abonyi-Tóth, et al.
Magyar Onkologia
|
June 10, 2011
[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy]
Judit Moldvay, Judit Pápay, Rita Puskás, et al.
Magyar Onkologia
|
July 11, 2014
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission]
Judit Moldvay, Judit Pápay, Ilona Kovalszky, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 10, 2007
Distinct claudin expression profile in histologic subtypes of lung cancer
Judit Moldvay, Márta Jäckel, Csilla Páska, et al.
Oncotargets and Therapy
|
May 23, 2015
Lung cancer drug therapy in Hungary - 3-year experience
Judit Moldvay, György Rokszin, Zsolt Abonyi-Tóth, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 104) with videos related to
Sort By:
Page
of 11
Pathology Oncology Research : POR
|
December 27, 2006
Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues
Katalin Derecskei, Judit Moldvay, Krisztina Bogos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 15, 2016
Differences in the Epidemiology of Rare EGFR Mutations in Different Populations
Zoltan Lohinai, Gyula Ostoros, Judit Moldvay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 23, 2015
Reply to Rare Versus Artifactual EGFR Mutations
Zoltan Lohinai, Gyula Ostoros, Judit Moldvay, et al.
Magyar Onkologia
|
December 18, 2010
[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer]
György Losonczy, Csaba Máthé, Veronika Müller, et al.
Biomarker Research
|
February 23, 2016
A robust prognostic gene expression signature for early stage lung adenocarcinoma
Marcin Krzystanek, Judit Moldvay, David Szüts, et al.
Magyar Onkologia
|
April 11, 2013
[Analysis of drug therapy of lung cancer in Hungary]
Judit Moldvay, György Rokszin, Zsolt Abonyi-Tóth, et al.
Magyar Onkologia
|
June 10, 2011
[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy]
Judit Moldvay, Judit Pápay, Rita Puskás, et al.
Magyar Onkologia
|
July 11, 2014
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission]
Judit Moldvay, Judit Pápay, Ilona Kovalszky, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 10, 2007
Distinct claudin expression profile in histologic subtypes of lung cancer
Judit Moldvay, Márta Jäckel, Csilla Páska, et al.
Oncotargets and Therapy
|
May 23, 2015
Lung cancer drug therapy in Hungary - 3-year experience
Judit Moldvay, György Rokszin, Zsolt Abonyi-Tóth, et al.
Page
of 11